Nitrogen Containing Reactant Patents (Class 530/405)
-
Patent number: 7906629Abstract: Activated haptens useful for generating immunogens to HIV protease inhibitors, immunogens useful for producing antibodies to HIV protease inhibitors, and antibodies and labeled conjugates useful in immunoassays for the HIV protease inhibitor saquinavir. The novel haptens feature an activated functionality at the central, non-terminal hydroxyl group. Also described are monoclonal antibodies specific for saquinavir having less than 10% cross-reactivity with lopinavir, nelfinavir, amprenavir, ritonavir, and indinavir, and a murine hybridoma producing said antibodies.Type: GrantFiled: January 31, 2007Date of Patent: March 15, 2011Assignee: Roche Diagnostics Operations, Inc.Inventors: Gerald F. Sigler, Raymond A. Hui, Ina Deras, Erasmus Huber, Herbert W. Von Der Eltz
-
Patent number: 7893220Abstract: Novel conjugates of busulfan and novel busulfan immunogens derived from ?-substituted derivatives of busulfan and antibodies generated by these busulfan linked immunogens are useful in immunoassays for the quantification and monitoring of busulfan in biological fluids.Type: GrantFiled: July 9, 2008Date of Patent: February 22, 2011Assignee: Saladax Biomedical Inc.Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Shu He
-
Publication number: 20110038887Abstract: The present invention relates to a vaccine against Trypanosoma cruzi infection, useful in the prevention and/or treatment of the Chagas disease. More specifically, the present invention relates to a recombinant mutant trans-sialidase enzyme that can be used as an efficient vaccine, without side effects.Type: ApplicationFiled: March 14, 2007Publication date: February 17, 2011Applicants: VIB VZW, UNIVERSITEIT GENTInventors: Roland Contreras, Kristof De Vusser, Silvia Revelli
-
Publication number: 20110027810Abstract: The invention described herein relates to a method for combining antigen fragments of Toxoplasma gondii proteins, in the form of chimeric fusion products, and their use as diagnostic and immunogenic agents.Type: ApplicationFiled: July 1, 2010Publication date: February 3, 2011Applicant: KENTON S.R.L.Inventors: NICOLA GARGANO, ELISA BEGHETTO, ANDREA SPADONI
-
Publication number: 20110003314Abstract: The invention teaches derivatives of ascomycin and methods of preparing immunogens and other conjugates useful in immunoassays for quantitatively measuring concentrations of tacrolimus in patient specimens. Antibodies produced from the disclosed immunogens capable of binding to tacrolimus with cross-reactivity of no more than 5% with each of 15-O-demethyl tacrolimus, 31-O-demethyl tacrolimus, and 13,31-O-didemethyl tacrolimus, less than 40% with 13-O-demethyl tacrolimus, and less than 1% with cyclosporin, rapamycin, mycophenolic acid, prednisone, hydrocortisol, and prednisolone are described. Further, immunoassays for measuring the concentration of tacrolimus using such antibodies are taught.Type: ApplicationFiled: September 7, 2010Publication date: January 6, 2011Applicant: MICROGENICS CORPORATIONInventors: Vani Bodepudi, Lisa Charters, Rueyming Loor
-
Patent number: 7863427Abstract: Methods, compositions and kits are disclosed directed at haptens, immunogens and immnoassays for buprenorphine (BUP) and nor buprenorphine (norBUP). The method comprises providing in combination in a medium (i) a sample suspected of containing buprenorphine (BUP) or norbuprenorphine (norBUP) and (ii) an antibody raised against an immunogen of buprenorphine (BUP) or norbuprenorphine (norBUP). The medium is examined for the presence of a complex comprising a labeled hapten of buprenorphine (BUP) or norbuprenorphine (norBUP) where the presence of such as complex indicates the presence of the compound in the sample.Type: GrantFiled: April 12, 2007Date of Patent: January 4, 2011Assignee: Siemens Healthcare Diagnostics Inc.Inventors: Yi-Feng Zheng, Pratap Singh, Dorota Bolle, Hshiou-Ting Liu
-
Publication number: 20100322962Abstract: A substituted Norovirus capsid protein monomer, having only the P-domain and called an antigen-Norovirus P-domain monomer, includes a foreign antigen inserted into one or more of three surface loops present on each P-domain monomer by molecular cloning. The antigen-P-domain monomer can assemble spontaneously into an octahedral form, called an antigen-Norovirus P-particle, that is composed of 24 copies of the antigen-P-domain monomer. Each substituted P-domain monomer will contain one to three copies of the foreign antigen, for a total of 24-72 antigen copies on each antigen-P-particle. The antigen-P-particle is useful in methods for diagnosing, immunizing and treating individuals infected with a foreign virus, for example Rotavirus, and can serve as a carrier for presentation of foreign antigens for development of novel vaccines against many infectious and non-infectious diseases. The substituted Norovirus P-particles can be readily produced in E.Type: ApplicationFiled: June 9, 2010Publication date: December 23, 2010Inventors: Xi Jiang, Ming Tan
-
Publication number: 20100322958Abstract: Modified capsular saccharides comprising a blocking group at a hydroxyl group position on at least one of the monosaccharide units of the corresponding native capsular saccharide, wherein the blocking group is of the formula (Ia) or (Ib): —OX—Y (Ia) or —O—R1 (Ib) wherein X is C(O), S(O) or SO2; Y is NR1R2 or R3; R1 is C1-6 alkyl substituted with 1, 2 or 3 groups independently selected from hydroxyl, sulphydryl and amine; R2 is H or C1-6 alkyl; and R3 is C1-6 alkyl; processes for modifying a capsular saccharide with the blocking groups; saccharide-protein conjugates comprising the modified capsular saccharide; processes for making the saccharide-protein conjugates, pharmaceutical compositions comprising the modified capsular saccharides and/or saccharide-protein conjugates; and methods and uses of the same.Type: ApplicationFiled: January 11, 2008Publication date: December 23, 2010Inventors: Angela Bardotti, Alessandro Pianigiani, Francesco Berti, Paolo Costantino
-
Publication number: 20100303864Abstract: The invention relates to polynucleotides which are conserved or specific to one or more species of Streptococcus, Streptococcus species serotypes, and/or serotype isolates. In particular, the invention relates to polynucleotides from Streptococcus which are conserved or specific to one or more of the species of S. pneumoniae (“pneumococcus” or “S. pn.”), S. pyogenes (“group A streptococcus” or “GAS”), and S. agalactiae (“group B streptococcus” or “GBS”). The invention further relates to polynucleotides which are conserved or specific to one or more Streptococcal species serotypes, such as GBS serotypes Ia, Ib, II, III, IV, V, VI, VII, and VIII. The invention still further relates to polynucleotides which are conserved or specific to one or more clinical isolates of a Streptococcus species.Type: ApplicationFiled: June 9, 2010Publication date: December 2, 2010Inventors: Herve Tettelin, Vega Masignani
-
Patent number: 7837980Abstract: A protein containing one or more activatable groups, e.g., an antibody, is subjected to partial or complete reduction of one or more such bonds to form reactive groups; the resulting protein is reacted with a drug which is reactive with some of the reactive groups, such as certain radiometals, chelating agents, and toxins, so as to form a conjugate useful in, e.g., in vitro diagnosis, in vivo imaging, and therapy.Type: GrantFiled: March 2, 2005Date of Patent: November 23, 2010Assignee: Seattle Genetics, Inc.Inventors: Stephen C. Alley, Michael Torgov, Michael Sun
-
Publication number: 20100215686Abstract: The present application discloses an improved method for conducting saccharide-protein conjugation reactions using carbodiimide condensation chemistry. Depending the nature of the saccharide or protein carrier involved, the quality of the conjugate may be improved by adding one of the reaction components slowly to the reaction mixture. Immunogenic compositions are further provided comprising the saccharide-protein conjugates made by the methods disclosed.Type: ApplicationFiled: June 23, 2006Publication date: August 26, 2010Inventors: Ralph Leon Biemans, Pierre Duvivier
-
Patent number: 7776620Abstract: Novel hapten-carrier conjugates are capable of inducing the production of antibodies, in vivo, that specifically bind to nicotine. These conjugates comprise a nicotine hapten conjugated to an immunogenic carrier protein. The novel conjugates preserve the chirality of nicotine in its native (S)-(?) state, and have good stability properties. The conjugates are useful in formulating vaccines for active immunization, that are used to prevent and treat nicotine addiction. The antibodies raised in response to the nicotine hapten-carrier conjugate are used for passive immunization. These antibodies are administered for prevention and treatment of nicotine addiction.Type: GrantFiled: July 20, 2007Date of Patent: August 17, 2010Assignee: Nabi BiopharmaceuticalsInventors: Sofiane Ennifar, Ali Ibrahim Fattom, Robert B. Naso
-
Publication number: 20100204458Abstract: The present invention relates to a process for producing immunogenic polypeptides, comprising reducing disulfide bonds and blocking the resulting free thiol group with a blocking agent. The immunogenic peptides comprise a fragment of MAGE A3.Type: ApplicationFiled: March 12, 2010Publication date: August 12, 2010Inventors: Teresa Cabezon Silva, Joseph Cohen, Moncef Mohamed Slaoui, Carlota Vinals Bassols
-
Publication number: 20100184953Abstract: Novel stable, concentrated, biologically active and ready-to-use lipid-comprising drug delivery complexes and methods for their production are described. The biological activity of the complexes produced are comparable to the formulations prepared according to the prior art admixture method and upon purification, the complexes produced by the method of this invention are 50 to 500 fold more concentrated than the complexes formed by admixture. The method described herein provides for the large scale production of lipid-comprising drug delivery systems useful for gene therapy and other applications.Type: ApplicationFiled: December 14, 2009Publication date: July 22, 2010Applicant: University of PittsburghInventors: Leaf HUANG, Xiang GAO, Frank L. SORGI
-
Publication number: 20100143395Abstract: Provided is a fusion protein, which comprises human papillomavirus E7 antigen, virus capsid protein and molecular chaperone. Also provided is a macromolecule with immunogenicity aggregated by the fusion proteins. The particle morphology of the macromolecule is different from that of the virus-like particle. The macromolecule can be used for treatment of human papillomavirus relating diseases.Type: ApplicationFiled: June 18, 2008Publication date: June 10, 2010Inventor: Yunxu Cao
-
Publication number: 20100143399Abstract: The present application discloses a method for making an immunogenic composition comprising an improved way of conducting saccharide-protein conjugation reactions using carbodiimide condensation chemistry. Depending on the nature of the saccharide or protein carrier involved, the quality of the conjugate may be improved by adding one of the reaction components slowly to the reaction mixture. In addition, the conjugate is mixed with a staphylococcal antigen. Immunogenic compositions are further provided comprising the saccharide-protein conjugates made by the methods disclosed.Type: ApplicationFiled: January 2, 2008Publication date: June 10, 2010Applicant: GLAXOSMITHKLINE BIOLOGICALSInventors: Ralph Leon Biemans, Pierre Duvivier
-
Publication number: 20100105672Abstract: Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo by administering, in a therapeutic composition, are disclosed. Methods of preparing said conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of drug addiction, more particularly, cocaine addiction. Passive immunization using antibodies raised against conjugates of the instant invention is also disclosed. The therapeutic composition is suitable for co-therapy with other conventional drugs.Type: ApplicationFiled: August 3, 2009Publication date: April 29, 2010Inventors: Philip A. Swain, Victoria C. Schad, Julia L. Greenstein, Mark A. Exley, Barbara S. Fox, Stephen P. Powers
-
Patent number: 7687259Abstract: Provided is a method for noncovalently immobilizing a biomolecule on a solid substrate, including: providing a solid substrate having a first functional group attached thereto, the first functional group having a hydrogen bond donating ability; and reacting a mixture of a compound having a hydrogen bond accepting ability and a biomolecule functionalized with a second functional group, with the surface of the substrate, the second functional group having a hydrogen bond donating ability, in order to noncovalently immobilize the biomolecule on the substrate.Type: GrantFiled: June 25, 2008Date of Patent: March 30, 2010Assignee: Samsung Electronics Co., Ltd.Inventors: Nam Huh, Jong-myeon Park
-
Patent number: 7678551Abstract: Generally, the present invention relates to lamotrigine analogs that have substituents at the triazine 3-position and on the benzene 4-position and 5-position. The lamotrigine analogs can include immunogenic moieties that can be used to prepare anti-lamotrigine antibodies, or antigenic moieties that can be used in immunodiagnostic assays for lamotrigine. Also, the lamotrigine analog can include tracer moieties for detecting the presence or amount of the analog during an immunodiagnostic assay. Additionally, the lamotrigine analogs can be used in immunodiagnostic assays to compete with lamotrigine for binding with anti-lamotrigine antibodies.Type: GrantFiled: October 20, 2005Date of Patent: March 16, 2010Assignee: Seradyn, Inc.Inventors: Anlong Ouyang, Lili Arabshahi, Mark Roberts, Melissa Wall
-
Publication number: 20100040644Abstract: Methods for making an immunogenic conjugate that includes a hapten or an antigen covalently linked to a carrier. The methods include reacting a first agent with a dihydrazide resulting in a hydrazine-modified first agent, wherein the first agent is a hapten, an antigen or a carrier; reacting a second agent with a benzaldehyde compound resulting in a benzaldehyde-modified second agent, wherein the second agent is a hapten, an antigen or a carrier, provided that the first agent or the second agent is a carrier; and reacting the hydrazine-modified first agent with the benzaldehyde-modified second agent resulting in an immunogenic conjugate comprising a hapten or an antigen covalently linked to a carrier via a hydrazone linkage.Type: ApplicationFiled: October 20, 2009Publication date: February 18, 2010Inventors: Rachel Schneerson, Joanna Kubler-Kielb, Fathy Majadly, Stephen H. Leppla, John B. Robbins, Darrell T. Liu, Joseph Shiloach
-
Patent number: 7632928Abstract: An antibody and immunogen for generating an antibody to nitrofuran and/or nitrofuran metabolite such as tissue or protein bound nitrofuran metabolites. Nitrofurans and and/or nitrofuran metabolites in a biological sample can be detected by contacting the sample with the antibodies to form a complex that can be detected. The antibodies may also be incorporated into test kits for the detection of nitrofuran and/or nitrofuran metabolites.Type: GrantFiled: October 18, 2006Date of Patent: December 15, 2009Assignee: Charm Sciences, IncInventors: Say-Jong Law, Stanley E. Charm, Steven J. Saul
-
Patent number: 7625736Abstract: Methods for making an immunogenic conjugate that includes a hapten or an antigen covalently linked to a carrier. The methods include reacting a first agent with a dihydrazide resulting in a hydrazino-modified first agent, wherein the first agent is a hapten, an antigen or a carrier; reacting a second agent with a benzaldehyde compound resulting in a benzaldehyde-modified second agent, wherein the second agent is a hapten, an antigen or a carrier, provided that the first agent or the second agent is a carrier; and reacting the hydrazine-modified first agent with the benzaldehyde-modified second agent resulting in an immunogenic conjugate comprising a hapten or an antigen covalently linked to a carrier via a hydrazone linkage.Type: GrantFiled: December 6, 2004Date of Patent: December 1, 2009Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Rachel Schneerson, Joanna Kubler-Kielb, Fathy Majadly, Stephen H. Leppla, John B. Robbins, Darrell T. Liu, Joseph Shiloach
-
Patent number: 7611889Abstract: Provided is a method for noncovalently immobilizing a biomolecule on a solid substrate, including: providing a solid substrate having a first functional group attached thereto, the first functional group having a hydrogen bond donating ability; and reacting a mixture of a compound having a hydrogen bond accepting ability and a biomolecule functionalized with a second functional group, with the surface of the substrate, the second functional group having a hydrogen bond donating ability, in order to noncovalently immobilize the biomolecule on the substrate.Type: GrantFiled: February 7, 2005Date of Patent: November 3, 2009Assignee: Samsung Electronics Co., Ltd.Inventors: Nam Huh, Jong-myeon Park
-
Publication number: 20090215686Abstract: The present invention includes various NK1-based polypeptides and polynucleotides, related compositions, methods of modulating Met activity in a cell, and related methods of treatment. Also, the present invention includes a method for designing an antagonist of a receptor tyrosine kinase from a receptor tyrosine kinase agonist.Type: ApplicationFiled: March 5, 2008Publication date: August 27, 2009Inventors: Huaqiang Eric Xu, Ermanno Gherardi
-
Patent number: 7572644Abstract: A novel hydrogel copolymer, a substrate coated with the copolymer, a method of producing a microarray using the copolymer, and a microarray produced by the method are provided. The use of the hydrogel copolymer makes efficient removal of protein and high integration of nucleic acid and protein on a substrate for a microarray possible.Type: GrantFiled: January 17, 2006Date of Patent: August 11, 2009Assignee: Samsung Electronics Co., Ltd.Inventors: In-ho Lee, Jun-hong Min, Su-hyeon Kim
-
Publication number: 20090092632Abstract: Methods for preparing complex multivalent immunogenic conjugates that include simultaneously reacting a plurality or immunogenic-distinct polysaccharides with at least one protein to make the complex multivalent immunogenic conjugates. The simultaneous reaction involves reaction of a hydrazide group on one reactant with an aldehyde or cyanate ester group on the other reactant.Type: ApplicationFiled: September 15, 2008Publication date: April 9, 2009Inventor: Che-Hung Robert Lee
-
Publication number: 20080280307Abstract: The invention described herein relates to a method for combining antigen fragments of Toxoplasma gondii proteins, in the form of chimeric fusion products, and their use as diagnostic and immunogenic agents.Type: ApplicationFiled: February 27, 2006Publication date: November 13, 2008Inventors: Nicola Gargano, Elisa Beghetto, Andrea Spadoni
-
Patent number: 7423131Abstract: Novel conjugates of busulfan and novel busulfan immunogens derived from ?-substituted derivatives of busulfan and antibodies generated by these busulfan linked immunogens are useful in immunoassays for the quantification and monitoring of busulfan in biological fluids.Type: GrantFiled: October 6, 2006Date of Patent: September 9, 2008Assignee: Saladax Biomedical Inc.Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Shu He
-
Patent number: 7420043Abstract: The invention provides derivatives of efavirenz and methods of making derivatives of efavirenz. The derivatives include immunogenic compounds for producing antibodies to efavirenz and labeled efavirenz tracers. These compounds are useful in immunoassay methods for determining efavirenz.Type: GrantFiled: December 10, 2003Date of Patent: September 2, 2008Assignee: Roche Diagnostics Operations, Inc.Inventors: Mitali Ghoshal, Gerald Sigler, Anlong Ouyang
-
Patent number: 7371829Abstract: The invention provides haptens, immunogens comprising such haptens coupled to an antigenicity-conferring carrier material, conjugates comprising such haptens bonded to a labelling agent as well as, antibodies raised against such immunogens and capable of binding with ketamine and its primary metabolite, norketamine.Type: GrantFiled: January 31, 2003Date of Patent: May 13, 2008Assignee: Randox Laboratories LimitedInventors: Robert Ivan McConnell, Elouard Benchikh, Stephen Peter Fitzgerald, John Victor Lamont
-
Patent number: 7364911Abstract: The invention provides methods for labeling a molecule by contacting a sample molecule with a solid support coupled to a chemical group comprising a cleavable functional group, one or more functional groups, and a reactive group for the sample molecule, under conditions allowing the sample molecule to covalently bind to the reactive group; and cleaving the cleavable functional group, thereby releasing the sample molecule comprising the one or more functional groups, which can be a tag. The invention also provides a solid support covalently coupled to a chemical group comprising a cleavable functional group, a mass spectrometry tag and a reactive group for covalently attaching a sample molecule, wherein the cleavable functional group, the tag and the reactive group are positioned relative to each other to allow transfer of the tag to the sample molecule upon cleavage of the cleavable functional group.Type: GrantFiled: May 14, 2002Date of Patent: April 29, 2008Inventors: Rudolf H. Aebersold, Huilin Zhou, Beate Rist, George J. Vella, Subhasish Purkayastha, Sasi Pillai
-
Patent number: 7351797Abstract: The invention provides intermediates and methods that allow for site-specific modification of peptides after synthesis. Accordingly, functional molecules can be selectively linked to a peptide to provide a peptide conjugate having altered biological, chemical, or physical properties. For example, functional molecules (e.g. biophysical probes, peptides, polynucleotides, and therapeutic agents) can be linked to a peptide to provide a peptide conjugate having differing and useful properties. The invention also provides a compound of formula (III): wherein: R6 is a peptide; X is a direct bond or a linking group; R7 is hydrogen, (C1-C6)alkyl, an amino protecting group, or a radical comprising one or more aminooxy groups; Y is a direct bond or a linking group; and D is a functional molecule.Type: GrantFiled: September 29, 2000Date of Patent: April 1, 2008Assignee: The Scripps Research InstituteInventors: Klaus M. Hahn, Steven J. Bark
-
Patent number: 7344895Abstract: A process for synthesizing nanoparticles, in particular metal salt nanoparticles. To the synthesis mixture is added a modifying reagent which binds, by means of a first functional group, to the nanoparticle surface and which carries a second functional group for binding to molecules which are specifically selected in dependence on the subsequent use of the nanoparticles. This dispenses with a postsynthetic, separate, application-specific modification step. A new substance class, the pentaalkyl iminobis(methylenephosphono)carboxylates, are particularly suitable for this purpose.Type: GrantFiled: December 6, 2003Date of Patent: March 18, 2008Assignee: Bayer Technology Services GmbHInventors: Burkhard Köhler, Kerstin Bohmann, Werner Hoheisel, Markus Haase, Stefan Haubold, Christiane Meyer, Thorsten Heidelberg
-
Patent number: 7326776Abstract: For certain mixed mode resins having anionic character, a ligand is joined to a solid support via a linkage that includes a mercapto-, ether- or amino-containing moiety. A suitable ligand comprises an aromatic group, a heteroaromatic group, or a heterocyclic group, optionally fused, that is sulfate-, sulfonate-, phosphonate- or phosphate-substituted and that is linked to such a moiety. These resins possess an anionic character under conditions prescribed for their use. Separation of a biological substance, such as a peptide or protein, can be accomplished with a resin of this type via a change in the pH of eluants, thereby effecting adsorption and desorption.Type: GrantFiled: September 14, 2006Date of Patent: February 5, 2008Assignee: Pall CorporationInventors: Egisto Boschetti, Pierre Girot
-
Patent number: 7279165Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and in particular an A?1-6 peptide-VLP-composition. More specifically, the invention provides a composition comprising a virus-like particle and at least one A?1-6 peptide bound thereto. The invention also provides a process for producing the conjugates and the ordered and repetitive arrays, respectively. The compositions of the invention are useful in the production of vaccines for the treatment of Alzheimer's disease and as a pharmaccine to prevent or cure Alzheimer's disease and to efficiently induce immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context.Type: GrantFiled: July 18, 2003Date of Patent: October 9, 2007Assignee: Cytos Biotechnology AGInventors: Martin F. Bachmann, Alain Tissot, Rainer Ortmann, Rainer Lūönd, Matthias Staufenbiel, Peter Frey
-
Patent number: 7279562Abstract: Provided are rapamycin conjugates which are useful as immunogenic molecules for the generation of antibodies specific for rapamycin, for measuring levels of rapamycin or derivatives thereof; for isolating rapamycin binding proteins; and detecting antibodies specific for rapamycin or derivatives thereof. This invention also provides a rapamycin specific monoclonal antibody.Type: GrantFiled: April 18, 2002Date of Patent: October 9, 2007Assignee: WyethInventors: Katherine L. Molnar-Kimber, Craig E. Caufield, Timothy D. Ocain
-
Patent number: 7276347Abstract: Novel conjugates of protected aldehyde active metabolites of cyclophosphamide including reagents and immunogens thereof and monoclonal antibodies generated by these immunogens, said reagents and immunogens useful in immunoassays for the monitoring of the active metabolites of cyclophosphamide in patients being treated with cyclophosphamide.Type: GrantFiled: July 20, 2005Date of Patent: October 2, 2007Assignee: Saladax Biomedical Inc.Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Dennis Stocker
-
Patent number: 7267994Abstract: The present invention provides compositions and methods for detecting, analyzing, and identifying biomolecules. More particularly, the invention provides Element Coded Affinity Tags comprising a metal chelate and a metal ion and methods of using the tags to detect, analyze, and identify biomolecules including polypeptides, nucleic acids, lipids, and polysaccharides.Type: GrantFiled: May 24, 2004Date of Patent: September 11, 2007Assignee: Regents of the University of CaliforniaInventors: Claude F. Meares, Carlito B. Lebrilla, Nathaniel G. Butlin, Sarah M. Cheal, Todd M. Corneillie, Susan Lee, Paul A. Whetstone, Nicolas L. Young
-
Patent number: 7247502Abstract: Novel hapten-carrier conjugates are capable of inducing the production of antibodies, in vivo, that specifically bind to nicotine. These conjugates comprise a nicotine hapten conjugated to an immunogenic carrier protein. The novel conjugates preserve the chirality of nicotine in its native (S)-(?) state, and have good stability properties. The conjugates are useful in formulating vaccines for active immunization, that are used to prevent and treat nicotine addiction. The antibodies raised in response to the nicotine hapten-carrier conjugate are used for passive immunization. These antibodies are administered for prevention and treatment of nicotine addiction.Type: GrantFiled: August 3, 2004Date of Patent: July 24, 2007Assignee: Nabi BiopharmaceuticalsInventors: Sofiane Ennifar, Ali Ibrahim Fattom, Robert B. Naso
-
Patent number: 7230088Abstract: The invention discloses compounds and compositions for dual phototherapy and combined therapy and diagnosis of tumors and other lesions. The compounds have a Dye that, when photoactivated, operates via Type I and/or Type II mechanisms. Other Dye or azide components may operate by the same or different mechanisms. Selection of particular components in a compound, and formulation of the compound(s) in a composition permit different activation wavelengths to be used for different therapies. A targeting moiety may be added to the compound or composition so that the Dye locates at a particular site, such as a hormone-sensitive tumor, for diagnosis and/or treatment. The compounds and compositions may be incorporated within liposomes.Type: GrantFiled: October 14, 2003Date of Patent: June 12, 2007Assignee: Mallinckrodt, Inc.Inventors: Raghavan Rajagopalan, Samuel I. Achilefu, Joseph E. Bugaj, Richard B. Dorshow, Muthunadar P. Periasamy
-
Patent number: 7229782Abstract: The present invention is directed antibodies specific to multiple beta blockers, as well as immunogens used to produce the antibodies and immunoassay kits and methods for using the antibodies.Type: GrantFiled: August 3, 2004Date of Patent: June 12, 2007Assignee: LabOne, Inc.Inventor: Liuming Yu
-
Patent number: 7223553Abstract: Immunoassays for the detection of everolimus are provided. Compounds for producing antibodies for everolimus, as well as antibodies produced therefrom, are also provided.Type: GrantFiled: February 13, 2006Date of Patent: May 29, 2007Inventors: Mark Roberts, Lili Arabshahi, Jared Boyd, Christopher T. Dennis, Peter Marbach, George Aaron, Deng Hwang, Alexei Boris Shvets
-
Patent number: 7220842Abstract: Methods, compositions and kits are disclosed directed at haptens, immunogens and immunoassays for buprenorphine (BUP) and nor buprenorphine (norBUP). The method comprises providing in combination in a medium (i) a sample suspected of containing buprenorphine (BUP) or norbuprenorphine (norBUP) and (ii) an antibody raised against an immunogen of buprenorphine (BUP) or norbuprenorphine (norBUP). The medium is examined for the presence of a complex comprising a labeled hapten of buprenorphine (BUP) or norbuprenorphine (norBUP) where the presence of such as complex indicates the presence of the compound in the sample.Type: GrantFiled: April 5, 2004Date of Patent: May 22, 2007Assignee: Dade Behring Inc.Inventors: Yi-Feng Zheng, Pratap Singh, Dorota Bolle, Hshiou-Ting Liu
-
Patent number: 7214545Abstract: The present invention provides compositions and methods for detecting, analyzing, and identifying biomolecules. More particularly, the invention provides Element Coded Affinity Tags comprising a metal chelate and a metal ion and methods of using the tags to detect, analyze, and identify biomolecules including polypeptides, nucleic acids, lipids, and polysaccharides.Type: GrantFiled: April 28, 2004Date of Patent: May 8, 2007Assignee: The Regents of the University of CaliforniaInventors: Claude F. Meares, Paul A. Whetstone, Todd M. Corneillie, Nathaniel G. Butlin
-
Patent number: 7211409Abstract: A compound of formula (1) and an immunoassay method for quantitative determination of dioxins in a sample using as a standard the compound of the following formula (1): wherein R1, R2, R3 and R4 may be the same or different and represent chlorine or hydrogen, n is an integer from 1 to 10, and Z represents an amino acid residue or peptide.Type: GrantFiled: August 18, 2003Date of Patent: May 1, 2007Assignees: Toyo Boseki Kabushiki Kaisha, Takuma Co., Ltd.Inventors: Shigeaki Nishii, Kazuhiro Matsui, Takuya Ishibashi, Masanori Oka, Hiroki Fujihira, Hirotsugu Mishima, Shizuo Kataoka
-
Patent number: 7211445Abstract: A method is provided for covalently linking carbohydrates, proteins, nucleic acids, and other biomolecules under neutral conditions, using a Diels-Alder cycloaddition reaction. In an example, activated carbon-carbon double bonds were attached to free amino sites of a carrier protein, and a conjugated diene was attached to a carbohydrate hapten. Spontaneous coupling of the carbohydrate and the protein components under very mild conditions provided glycoconjugates containing up to 37 carbohydrate hapten units per carrier protein molecule. The method is also applicable to the immobilization of biomolecules on gel or solid supports. The conjugated products are useful as immunogens and as analytical and diagnostic reagents.Type: GrantFiled: October 22, 2003Date of Patent: May 1, 2007Assignee: The United States of America as Represented by the Secretary of the Department of Health and Human ServicesInventor: Vince Pozsgay
-
Patent number: 7208148Abstract: The invention concerns a derivative of viral regulatory protein or a fragment of viral regulatory protein or of the alpha interferon or a fragment of alpha interferon, which is carboxymethylated, a method for preparing, use of the resulting product in a method of treatment for the human or animal body, a pharmaceutical composition and a vaccine containing as active principle, at least one of the carboxymethylated proteins or fragments.Type: GrantFiled: March 21, 2005Date of Patent: April 24, 2007Assignee: Neovacs S.A.Inventors: Daniel Zagury, Jean-François Zagury
-
Patent number: 7205161Abstract: Sensors for determining the presence and concentration of biomolecules in a biological sample are provided in the form of polymer brushes, which comprise a substrate having a surface modified with a hydrophobic polymer segment, attached to which is a water-dispersible or water-soluble polymer segment having functional groups that bind probes. The method of synthesis of such sensors preferably includes use of controlled free radical polymerization techniques, which allows for controlled architecture polymers to modify the surface of the substrate, and the use of monomers possessing functional groups which do not require activation prior to probe attachment. In this manner functional groups in the polymer chain are removed from the surface, which allows for solution chemistry to be more realistically reproduced with the benefits of a solid bound probe.Type: GrantFiled: January 10, 2002Date of Patent: April 17, 2007Assignee: Symyx Technologies, Inc.Inventors: Gerrit Klaerner, Didier Benoit, Dominique Charmot, Srinivas Nomula, Marcelo Eduardo Piotti, Laura T. Mazzola
-
Patent number: 7205116Abstract: Novel conjugates of 5-fluoro-uracil and novel 5-fluoro-uracil immunogens and monoclonal antibodies generated by these immunogens which are useful in immunoassays for the quantification and monitoring of 5-fluoro-uracil in biological fluids.Type: GrantFiled: February 2, 2006Date of Patent: April 17, 2007Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Dennis Stocker
-
Patent number: RE40596Abstract: Monoclonal antibodies to rapamycin and to 40-O-alkylated derivatives of rapamycin are provided, together with novel haptens, immunogenic conjugates, and processes for making them and assay kits for using them.Type: GrantFiled: February 6, 2007Date of Patent: December 2, 2008Assignee: Novartis AGInventors: Richard Sedrani, Valerie Quesniaux Ryffel